Razvoj definicije i reinterpretacija kardiovaskularne toksičnosti.

One of the guiding principles of cardio-oncology practice is to minimize the unnecessary interruption of antineoplastic therapy. The overall goal of the specialty is to ensure that cancer patients receive the best possible anticancer therapy safely, while minimizing cancer therapy-related cardiovascular toxicity (CTR-CVT) during oncology care. In this paper, we describe prior and current definitions of CTR-CVT and briefly present the landmark CARDIOTOX registry, as well as corresponding parts of the recently published, first cardio-oncology guideline of the European Society of Cardiology. In our paper, we aim to provide insight into the cardio-oncology-related aspects of precision medicine. [ABSTRACT FROM AUTHOR]